These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange. Kawabe M; Yamamoto I; Katsuma A; Hayashi N; Komatsuzaki Y; Nakada Y; Shimizu A; Tanno Y; Ohkido I; Tsuboi N; Suzuki K; Shimada T; Ogasawara Y; Sugiyama K; Aiba K; Yokoo T CEN Case Rep; 2016 Nov; 5(2):232-237. PubMed ID: 28508984 [TBL] [Abstract][Full Text] [Related]
26. Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis. Tarragón B; Ye N; Gallagher M; Sen S; Portolés JM; Wang AY Clin Kidney J; 2021 Aug; 14(8):1894-1900. PubMed ID: 34345412 [TBL] [Abstract][Full Text] [Related]
27. Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy. Snozek CLH; Kinard TN; Adamski J J Clin Apher; 2018 Jun; 33(3):439-443. PubMed ID: 29427353 [TBL] [Abstract][Full Text] [Related]
28. Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review. Huang J; Sun C; Su H; Zhang C; Xiong J Kidney Blood Press Res; 2019; 44(4):858-869. PubMed ID: 31352451 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995 [TBL] [Abstract][Full Text] [Related]
30. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509 [TBL] [Abstract][Full Text] [Related]
32. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112 [TBL] [Abstract][Full Text] [Related]
33. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909 [TBL] [Abstract][Full Text] [Related]
34. Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery. Khalafallah AA; Loi SW; Love S; Mohamed M; Mace R; Khalil R; Girgs M; Raj R; Mathew M Mediterr J Hematol Infect Dis; 2013; 5(1):e2013007. PubMed ID: 23350020 [TBL] [Abstract][Full Text] [Related]
35. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study. Yadav P; Sathick IJ; Leung N; Brown EE; Cook M; Sanders PW; Cockwell P Blood Cancer J; 2020 Mar; 10(3):28. PubMed ID: 32127527 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy. Curti A; Schwarz A; Trachsler J; Tomonaga Y; Ambühl PM PLoS One; 2016; 11(7):e0159942. PubMed ID: 27467401 [TBL] [Abstract][Full Text] [Related]
38. The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review. Koniman R; Teo SH; Kaushik M; Nagarajan C; Tan MSY; Tan HK; Ramirez MEG; Lim CC; Semin Dial; 2023 Jan; 36(1):12-17. PubMed ID: 35840146 [TBL] [Abstract][Full Text] [Related]
39. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797 [TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]